@entity2142 during extracorporeal membrane oxygenation (ECMO) leads to increased levels of cell-free hemoglobin (FHb). Our aim was to investigate whether FHb levels are associated with @entity842 (NO) consumption and clinical outcomes. A prospective observational study was performed involving pediatric @entity1 on ECMO. Blood samples were collected before, during, and after the ECMO run, and plasma was evaluated for FHb, @entity7672 , and NO consumption. Clinical data were collected including baseline @entity1 characteristics, indications for ECMO, circuit changes, and mortality. Correlations between laboratory measures and associations between laboratory measures and clinical observations were evaluated. Twenty-three @entity1 (11 male, 17 neonates) were enrolled with a median weight of 3.1 kg (interquartile range, 2.8-14.0 kg) and median ECMO run of 12 days (interquartile range, 5-19 day). There was a significant increase in FHb over time on ECMO (p = .007), and significant correlations were present between NO consumption and both FHb (r = .41, p = .01) and @entity7672 levels (r = .98, p < .0001). @entity1 on ECMO for @entity295 (n = 6) had lower average levels of @entity7672 (mean [standard deviation {SD}] 14.5 [4.4] versus 19.0 [5.0]  M, p = .07) and NO consumption (mean [SD] 15.8 [4.1] versus 19.8 [3.7]  M, p = .04) during ECMO than @entity1 with other indications. In the 3 days leading up to a circuit change, there were increases in mean total cell-free hemoglobin levels (24%/day, p = .08), @entity7672 (37%/day, p = .005), and NO consumption (40%/day, p = .006) (n = 5). There were no significant associations identified between peak or average plasma measures of @entity2142 and type of ECMO (venovenous versus venoarterial) or mortality. For @entity1 on ECMO, we observed a strong correlation between increased levels of plasma FHb and elevations in @entity7672 and NO consumption; however, these changes were not associated with increased mortality. Increased @entity2142 before circuit changes may be both a marker and a contributor to circuit failure.

Hemolysis-Associated XXXX Dysregulation during Extracorporeal Membrane Oxygenation.

@entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients', 'patient'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity7672 :: ('CHEBI:7861', 'Chemical') :: ['oxyhemoglobin'] @entity2142 :: ('MESH:D006461', 'Disease') :: ['hemolysis', 'Acute intravascular hemolysis']
@entity842 :: (MESH:D009569,Chemical) :: ['Nitric Oxide']
